

Alzinova publishes annual report for 2025

Alzinova AB (publ) (“Alzinova” or the “Company”) hereby publishes its annual report for the financial year 2025. The annual report, which is attached to the press release, can also be downloaded from the Company’s website, <https://www.alzinova.com/investors/financial-reports/>.

The following is an excerpt from the auditor’s report. The full auditor’s report can be found in the annual report.

Material uncertainty related to going concern

We would like to draw attention to the information in the Directors’ Report on page 31, which describes that the Company is dependent on raising additional capital in order to secure the continuation of its operations for a period of twelve months from the balance sheet date. Should such financing not be obtained, this may give rise to uncertainty regarding the Company’s future operations. These conditions indicate the existence of a material uncertainty related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Statement from the company

Following the completed share issue and existing loan commitment, the Company has not yet fully secured financing for the entire year of 2026. The Board of Directors is actively pursuing several financing initiatives to strengthen the Company’s financial position; however, these are subject to uncertainty regarding timing, scope and terms. However, based on ongoing processes and discussions, the Board of Directors assesses that there are reasonable prospects of securing the necessary financing and thereby supporting continued operations for the foreseeable future.

For more information, please contact:

Tord Labuda, CEO
E-mail: info@alzinova.com

Erik Kullgren, CFO
E-mail: info@alzinova.com

About Alzinova AB

Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer’s disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer’s disease. Alzinova’s patented A β CC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer’s disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com

Note: This annual report is in all respects a translation of the Swedish original. In the event of any discrepancies between this translation and the Swedish original, the latter shall prevail.